Related Experiment Video
Updated: Jul 3, 2026

Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome
Kevin Barraclough1, William G Liddell, Jennifer du Toit
1Hoyland House General Practice, Painswick, Glos, UK.
Background:
Polymyalgia rheumatica (PMR) is common and is usually diagnosed and managed in primary care. There are no generally accepted primary care criteria for diagnosis.
Objectives:
To identify what features are used to diagnose PMR, to benchmark these against diagnostic criteria and to identify features at diagnosis with prognostic significance.
Methods:
This was a retrospective cohort study of all patients diagnosed with PMR in three UK general practices between January 1994 and December 2003. The medical records were examined for features of PMR. The duration of steroid treatment was used as a proxy for duration of disease. Analysis of prognostic predictors was by Cox proportional hazards models.
Results:
One hundred and eighty-three patients were identified, giving an overall annual incidence of 11.3 per 10 000 patients aged 50 or over. The median age at diagnosis was 75 (interquartile range 69, 79) years: 138 (75%) were female. The most common diagnostic features were proximal muscle pain in 151 (82%), raised inflammatory markers in 160 (87%), clinical response to corticosteroids in 166 (91%) and normalization of inflammatory markers in 147 (81%). Twenty (11%) had normal inflammatory indices. The median duration of treatment was 1.4 years (interquartile range 0.8, 2.4). Female sex and raised inflammatory markers were independently associated with longer treatment: female hazard ratio 1.5 (1.0, 2.2) P = 0.047 and raised inflammatory markers 2.0 (1.2, 3.2) P = 0.01.
Conclusions:
Primary care practitioners do not use established criteria to diagnose PMR and sometimes diagnose the condition even when inflammatory markers are normal. This exposes patients to a risk of inappropriate steroid use.
Insights
Primary care doctors often diagnose polymyalgia rheumatica (PMR) without standard criteria, sometimes even with normal inflammatory markers. This practice may lead to unnecessary corticosteroid use in patients.
Area of Science:
- Rheumatology
- Primary Care Medicine
- Clinical Epidemiology
Background:
- Polymyalgia rheumatica (PMR) is a common condition frequently managed in primary care settings.
- Currently, there is a lack of universally accepted diagnostic criteria for PMR within primary care.
Purpose of the Study:
- To determine the diagnostic features utilized by primary care practitioners for PMR.
- To compare these features against established diagnostic criteria.
- To identify prognostic indicators present at diagnosis that predict disease course.
Main Methods:
- A retrospective cohort study was conducted involving patients diagnosed with PMR in three UK general practices from 1994 to 2003.
- Medical records were analyzed to identify key diagnostic features of PMR.
- Duration of corticosteroid treatment served as a proxy for disease duration, and Cox proportional hazards models were used for prognostic analysis.
Main Results:
- 183 patients were identified, with an annual incidence of 11.3 per 10,000 individuals aged 50+.
- Common diagnostic features included proximal muscle pain (82%), elevated inflammatory markers (87%), and response to corticosteroids (91%).
- Female sex and elevated inflammatory markers were independently linked to longer treatment durations.
Conclusions:
- Primary care physicians often diagnose PMR without adhering to established criteria.
- The condition is sometimes diagnosed despite normal inflammatory marker levels.
- This diagnostic approach poses a risk of inappropriate corticosteroid exposure for patients.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease I: Introduction
Pericarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy IV: Restrictive Cardiomyopathy
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
